

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6070410

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LORI SHAFNER	11/29/2018
SCOTT T. ROTTINGHAUS	12/14/2018
RAJENDRA PRADHAN	11/29/2018
ANDREW DAMOKOSH	11/29/2018
XIANG GAO	03/22/2019
RECEIVING PARTY DATA	
Name:	ALEXION PHARMACEUTICALS, INC.
Street Address:	121 SEAPORT BOULEVARD
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02210
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16757512
CORRESPONDENCE DATA	
Fax Number:	(617)217-4699
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-217-4630
Email:	ipboston.docketing@nelsonmullins.com, melissa.stgermain@nelsonmullins.com
Correspondent Name:	NELSON MULLINS RILEY & SCARBOROUGH LLP
Address Line 1:	ONE POST OFFICE SQUARE, 30TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109-2127
ATTORNEY DOCKET NUMBER:	AXJ-224US
NAME OF SUBMITTER:	JILL GORNY SLOPER, ESQ.
SIGNATURE:	/Jill Gorny Sloper, Esq./
DATE SIGNED:	04/20/2020
Total Attachments: 9	
source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page1.tif	

source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page2.tif
source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page3.tif
source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page4.tif
source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page5.tif
source=Executed Assignment from Parent PCT -- AXJ-224US 4831-8024-4666 v.1#page6.tif
source=AXJ-224US - Executed Assignment Xiang Gao from Parent PCT -- 4847-2453-4970 v.1#page1.tif
source=AXJ-224US - Executed Assignment Xiang Gao from Parent PCT -- 4847-2453-4970 v.1#page2.tif
source=AXJ-224US - Executed Assignment Xiang Gao from Parent PCT -- 4847-2453-4970 v.1#page3.tif

ASSIGNMENT

WHEREAS WE, LORI SHAFNER, SCOTT T. ROTTINGHAUS, RAJENDRA PRADHAN AND ANDREW DAMOKOSH; for good and valuable consideration, the receipt of which is hereby acknowledged, have invented

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR
TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND
ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS),

described in an application for patent,

☐ the specification of which is about to be filed in the United States Patent Office (for utility 37 CFR 1.53(b) and design filings);

☐ is about to be filed in the United States Patent and Trademark Office as a Provisional Application;

☐ the specification of which is United States Application No. [], filed [];
and

☒ the specification of which is a Patent Cooperation Treaty Application, International Application No. PCT/US2018/057760, filed October 26, 2018 which claims the benefit of the following applications:

United States Provisional Application No. 62/577,244 filed October 26, 2017;
62/643,056 filed March 14, 2018; 62/643,608 filed March 15, 2018; 62/662,503 filed April 25, 2018; 62/685,505 filed June 15, 2018; and 62/685,425 filed June 15, 2018

☐ which was patented as United States Patent No. [];

AND,

WHEREAS Alexion Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of Delaware, and having a usual place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE we do hereby sell, assign and transfer unto ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with the entire right, title and interest in and to said application and such Letters Patent as may or shall issue on said invention, or any parts thereof, or any divisional, continuing, reissue or other application(s) based in whole or in part thereon; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby further convey all rights, including rights of priority, arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to

procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein.

We hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts that may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of any future applications including substitution, reissue, divisional or continuation applications, and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

We do hereby authorize and request the Commissioner of Patents and Trademarks of the United States, or foreign examining authority, to issue such Letters Patent as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors and assigns.

11-29-18
Date


Lori Shafner
Lori Shafner

Witness:

11-29-2018
Date


Kathleen Akura
Witness Name:

14 December 2018
Date



Scott T. Rottinghaus

Witness:

12/14/2018
Date



Witness Name: Darlene Suarez

11/29/2018
Date



Rajendra Pradhan

Witness:

11-29-2018
Date


Kathleen Aheron
Witness Name:


November 29, 2018
Date


Andrew Damokosh


Witness:

11-29-2018
Date


Witness Name:

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

S.V.P., Head of Intellectual Property

Signatory Title (print)

Alexion Pharmaceuticals, Inc.

Date: Jan. 11, 2019

ASSIGNMENT BY INVENTOR

I, Xiang GAO, of Guilford, Connecticut, for good and valuable consideration paid to me by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR
TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

described in an application

☐ Executed by me of even date herewith and about to be filed

or

☒ International Application No. PCT/US2018/057760, filed on October 26, 2018

This application claims the benefit of the following provisional application(s):

- ☒ Provisional Application No. 62/643,056, filed on March 14, 2018
Provisional Application No. 62/643,608, filed on March 15, 2018
Provisional Application No. 62/685,505, filed on June 15, 2018
Provisional Application No. 62/577,244, filed on October 26, 2017
Provisional Application No. 62/685,425, filed on June 15, 2018
Provisional Application No. 62/662,503, filed on April 25, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And I do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

March 22, 2019

Date

Xiang Gao

Xiang Gao

Witness:

March 22, 2019

Date

Anthony Tran

Witness Name:

Anthony Tran

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to **Alexion Pharmaceuticals, Inc.**, the Assignee, of which I am an authorized signatory.



Todd Spalding

Senior Vice President,
Head of Intellectual Property

SIGNATORY TITLE

Alexion Pharmaceuticals, Inc.

ASSIGNEE

Date: 04/05/19